title: Polyelectrolyte LbL microcapsules versus PLGA microparticles for immunization with a protein antigen.
abstract: The transition from organism-based traditional vaccines to the use of safer subunit vaccines has implemented the use of adjuvants to enhance immunogenicity. This study compares the potential of two types of polymeric microparticles as delivery systems for the model antigen ovalbumin. The delivery systems encompassed polyelectrolyte microcapsules, assembled via Layer-by-Layer technology, and PLGA microparticles fabricated by spray-drying. Mice were immunized subcutaneously either by a single injection or by two injections separated by four weeks with an equivalent dose of the OVA-loaded particles. Both particulate formulations mediated high, long-term IgG(1) responses whereas the IgG(2c) titers remained low. Additionally, Th1 and Th2 phenotype immune responses against OVA were assessed by quantifying the production of cytokines in CD4+ T-cells derived from the spleens of immunized mice at 6 months after the first injection. Immunization with particulate formulations led to significantly increased IL-2, IL-4, IL-10 and IFN-γ production by splenic CD4+ T-cells compared to control animals. LbL microcapsules and PLGA microparticles generated strong immune responses in vivo, characterized by a mixed Th1/Th2 type response with predominance of Th2 immunity. Both particulate formulations elicited a comparable type of immune response and appear to be promising for antigen delivery.
authors: Laboratory of General Biochemistry and Physical Pharmacy, Faculty of Pharmaceutical Sciences, Ghent University, Harelbekestraat 72, 9000 Ghent, Belgium.
authors: Marie-Luce
authors: ML
authors: De Temmerman
authors: Joanna
authors: J
authors: Rejman
authors: Roosmarijn E
authors: RE
authors: Vandenbroucke
authors: Stefaan
authors: S
authors: De Koker
authors: Claude
authors: C
authors: Libert
authors: Johan
authors: J
authors: Grooten
authors: Jo
authors: J
authors: Demeester
authors: Bruno
authors: B
authors: Gander
authors: Stefaan C
authors: SC
authors: De Smedt
mesh_terms: D000818:Animals; D000941:Antigens / Q000008:administration & dosage / Q000737:chemistry / Q000276:immunology; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D002214:Capsules; D016207:Cytokines / Q000276:immunology; D016264:Dextran Sulfate / Q000008:administration & dosage* / Q000737:chemistry; D004339:Drug Compounding / Q000379:methods*; D005260:Female; D007114:Immunization / Q000379:methods*; D007074:Immunoglobulin G / Q000276:immunology; D019344:Lactic Acid / Q000008:administration & dosage* / Q000737:chemistry; D051379:Mice; D008810:Mice, Inbred C57BL; D010047:Ovalbumin / Q000008:administration & dosage / Q000737:chemistry / Q000276:immunology; D010455:Peptides / Q000008:administration & dosage* / Q000737:chemistry; D011100:Polyglycolic Acid / Q000008:administration & dosage* / Q000737:chemistry; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer
chemical_list: D000941:Antigens; D002214:Capsules; D016207:Cytokines; D007074:Immunoglobulin G; D010455:Peptides; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; C015462:polyarginine; D011100:Polyglycolic Acid; D019344:Lactic Acid; D010047:Ovalbumin; D016264:Dextran Sulfate